Center on Health Equity & Access
Clinical
Health Care Cost
Health Care Delivery
Insurance
Policy
Technology
Value-Based Care

Free In-Person Regional Events Focused on Oncology and Population Health

All Coverage Event Coverage Interviews News

AJMC Journals Anniversary Author Forms Authors Nominate a Rising Leader Submit a Manuscript

Advances in the Treatment of Alzheimer Disease: Current Landscape and Future Directions : Episode 14

Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook

June 26, 2024

Derek van Amerongen, MD, MS
Soeren Mattke, MD, DSc

Opinion

Video

Looking to the future of Alzheimer disease treatment, the panel discusses key takeaways on the evolving therapeutic landscape.

EP: 1.The Clinical and Economic Implications of Alzheimer Disease Across Patients, Families, and the Health Care System

EP: 2.Recent Insights into the Pathophysiology of Alzheimer Disease

EP: 3.Genetic Aspects of Alzheimer Disease

EP: 4.The Patient Experience: From Symptoms to Diagnosis of Alzheimer Disease

EP: 5.Potential Consequences of Early Diagnosis of Alzheimer Disease

EP: 6.Criteria for Diagnosing Alzheimer Disease and the Role of Testing

EP: 7.Exploring the Economic Impact of Advanced Approaches for Diagnosing Alzheimer Disease

EP: 8.Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease

EP: 9.Clinical Decision-Making for Alzheimer Disease Management

EP: 10.Cost, Value, and Affordability of Treatment for Alzheimer Disease

EP: 11.Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates

EP: 12.Exploring the Influence of Administration Routes on Medical Costs and Caregiver Burden

EP: 13.Payer Coverage Considerations for New Treatments for Alzheimer Disease

Now Viewing

EP: 14.Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook

Video content above is prompted by the following question(s):

Looking to the future of Alzheimer disease treatment, what are your key takeaways on the evolving therapeutic landscape?

Related Content

ribbon for multiple sclerosis | Image credit: Pixel-Shot - stock.adobe.com

Identifying Signs of Presymptomatic MS, Radiologically Isolated Syndrome

August 26th 2025

Article

New insights reveal how early intervention in radiologically isolated syndrome can delay multiple sclerosis (MS) onset and improve patient outcomes.

While the use of genetic data helps minimize reverse causality, the study does not definitively establish causality between depression predisposition and MS outcomes. | Image credit: New Africa - stock.adobe.com.

Genetic Burden of Depression Linked to Increased MS Disease Activity and Disability

August 25th 2025

Article

New findings demonstrate an association between increased cumulative depression genetic burden and multiple sclerosis (MS) disease activity.

DYNE-251 Granted FDA Breakthrough Therapy Designation for DMD

August 13th 2025

Article

DYNE-251 received FDA breakthrough therapy designation, showcasing its potential for patients with Duchenne muscular dystrophy (DMD).

Following an investigation, the FDA confirmed that shipments of delandistrogene moxeparvovec can resume. | Image Credit: immimagery - stock.adobe.com

FDA Recommends Sarepta Resume DMD Gene Therapy Shipments for Ambulatory Patients

July 31st 2025

Article

Shipment of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), will resume following a voluntary pause.

cognition and alzheimer's disease/dementia | Image credit: Orawan - stock.adobe.com

Proposed SNAP Cuts Could Threaten Prevention for Cognitive Decline, Dementias

July 30th 2025

Article

Supplemental Nutrition Assistance Program (SNAP) benefits may slow cognitive decline in older adults, highlighting the importance of food assistance in combating Alzheimer disease and dementia risks.

kid with MS and doctor | Image credit: Halfpoint - stock.adobe.com

Emerging Strategies to Manage Pediatric-Onset Multiple Sclerosis

July 30th 2025

Article

Discover the latest insights on pediatric-onset multiple sclerosis, emphasizing early intervention and high-efficacy therapies for improved outcomes in children.

Related Content

Identifying Signs of Presymptomatic MS, Radiologically Isolated Syndrome

August 26th 2025

Article

New insights reveal how early intervention in radiologically isolated syndrome can delay multiple sclerosis (MS) onset and improve patient outcomes.

Genetic Burden of Depression Linked to Increased MS Disease Activity and Disability

August 25th 2025

Article

New findings demonstrate an association between increased cumulative depression genetic burden and multiple sclerosis (MS) disease activity.

DYNE-251 Granted FDA Breakthrough Therapy Designation for DMD

August 13th 2025

Article

DYNE-251 received FDA breakthrough therapy designation, showcasing its potential for patients with Duchenne muscular dystrophy (DMD).

FDA Recommends Sarepta Resume DMD Gene Therapy Shipments for Ambulatory Patients

July 31st 2025

Article

Shipment of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), will resume following a voluntary pause.

Proposed SNAP Cuts Could Threaten Prevention for Cognitive Decline, Dementias

July 30th 2025

Article

Supplemental Nutrition Assistance Program (SNAP) benefits may slow cognitive decline in older adults, highlighting the importance of food assistance in combating Alzheimer disease and dementia risks.

Emerging Strategies to Manage Pediatric-Onset Multiple Sclerosis

July 30th 2025

Article

Discover the latest insights on pediatric-onset multiple sclerosis, emphasizing early intervention and high-efficacy therapies for improved outcomes in children.

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777